SCHEMBL4070170

SCHEMBL4070170

O=P(O)(O)c1c(O)nnc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.46
LCK P06239 1/20 0.39
MAP2K3 P46734 1/20 0.39
MAP2K6 P52564 1/20 0.39
BTK Q06187 1/20 0.39
MAP3K19 Q56UN5 1/20 0.39
NEK10 Q6ZWH5 1/20 0.39
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA5A P35218 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ERN1 O75460 1/20 0.32
LMNA P02545 3/20 0.32
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 3/20 0.31
POLB P06746 2/20 0.31
MAPT P10636 2/20 0.31
MAPK1 P28482 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30876787 0.76 KDM4E (0.46) MEN1KMT2ACA2CA4CA5A
SCHEMBL28981702 0.71 GPR3 (0.59) GPR3LCKMAP2K3MAP2K6BTK
SCHEMBL23000057 0.70 CA2 (0.50) CA2CA4CA5AL3MBTL1MMP14
SCHEMBL6227884 0.68 GPR3 (0.54) GPR3LCKMAP2K3MAP2K6BTK
Phosphoric Acid SCHEMBL4846299 0.68 GPR3 (0.54) GPR3LCKMAP2K3MAP2K6BTK
Benzonaphthyridine SCHEMBL51197 0.67 GPR3 (1.00) GPR3LCKMAP2K3MAP2K6BTK
Benzonaphthyridine SCHEMBL30897319 0.67 GPR3 (1.00) GPR3LCKMAP2K3MAP2K6BTK
Benzonaphthyridine SCHEMBL29600756 0.67 GPR3 (1.00) GPR3LCKMAP2K3MAP2K6BTK
SCHEMBL10742424 0.67 GPR3 (0.41) GPR3LCKMAP2K3MAP2K6BTK
SCHEMBL350637 0.65 IDO1 (0.47) GPR3MEN1KMT2ACA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664046-B1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2009-06-17 EP disclosed
EP-1664046-B1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2009-06-17 EP disclosed
US-7462721-B2 Aza-quinolinol phosphonate integrase inhibitor compounds GILEAD SCIENCES, INC. (US) 2008-12-09 US disclosed
US-7462721-B2 Aza-quinolinol phosphonate integrase inhibitor compounds GILEAD SCIENCES, INC. (US) 2008-12-09 US disclosed
US-20070185007-A1 Aza-quinolinol phosphonate integrase inhibitor compounds JIN HAOLUN 2007-08-09 US disclosed
US-20070185007-A1 Aza-quinolinol phosphonate integrase inhibitor compounds JIN HAOLUN 2007-08-09 US disclosed
EP-1664046-A1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-06-07 EP disclosed
EP-1664046-A1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-06-07 EP disclosed
US-20050137199-A1 Inhibition of HiV integrase compounds GILEAD SCIENCES, INC. 2005-06-23 US disclosed
US-20050137199-A1 Inhibition of HiV integrase compounds GILEAD SCIENCES, INC. 2005-06-23 US disclosed
WO-2005028478-A1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-03-31 WO disclosed
WO-2005028478-A1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137199-A1 Inhibition of HiV integrase compounds CDKL5, CDKL1, CDKL3 GPR3 4065/4885LCK 709/4885MAP2K3 963/4885
US-20070185007-A1 Aza-quinolinol phosphonate integrase inhibitor compounds CDKL5, CDKL1, CDKL3 GPR3 4037/4885LCK 1081/4885MAP2K3 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.